Abstract
Traditional medicines derived from medicinal plants are used by about 60 per cent world population. Diabetes is an important human ailment officiating many from various walk of life in different countries including India. It providing to a major health problem, especially in the rural and subrural areas. Gymnema sylvestre R.Br. (Asclepiadaceae) is a herb distributed throughout the world. The leaves of the plant are widely used for the treatment of diabetes and as diuretic in India proprietary medicine. G. sylvestre, an Ayurvedic herb, came to be known as “destroyer of sugar” because, in ancient times, Ayurvedia physicians observed that chewing a few leaves of G. sylvestre suppressed the taste of sugar. It is used totally all over India for controlling blood sugar. This study was to determine effect of Gymnema sylvestre on the pharmacokinetics and pharmacodynamics of Oral hypoglycaemic drugs in streptozotocin induced diabetic rats. Results have indicated the negative effect of Gymnema Sylvestre on pharmacokinetics but positive effect on pharmacodynamics of oral hypoglycaemic drugs.
Keywords
Gymnema sylvestre, Pharmacokinetics, pharmacodynamics, Diabetes, Gliclazide.
Introduction
Many medicinal herbal and pharmaceutical drugs are therapeutic at one dose and toxic at another dose. Interactions between herbal and pharmaceutical drugs can increase or decrease the pharmacological or toxicological effects of either component, herbal drugs are traditionally used to decrease glucose concentrations in diabetic patients [1] could theoretically precipitate hypoglycaemia if taken in combination with conventional drugs.
Experimental studies have shown that herb-drug interactions have both a pharmacokinetic and pharmacodynamic basis, most of that are attributed to the induction or inhibition of hepatic and intestinal microsomal enzymes (primarily cytochrome P450) drug transporters [2]. Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin- dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class that act by stimulating β cells of the pancreas to release insulin [3].Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive k + channels. The binding to closing of the ion channels and leads to a resulting decrease in k + ion efflux leads to depolarization of the β cells. This opens voltage gated calcium channels in the β islet, that leads to exocytosis of insulin containing secretorty granules [4].Oral absorption of gliclazide is similar in patients and healthy volunteers, there is inter subject variation in time to reach peak plasma concentrations (tmax). Tmax and cmax are increased after repeated gliclazide administration. Steady state concentration is achieved after 2 days administration of 40 to 120 mg of gliclazide. Gliclazide has low volume of distribution (13 to 24L) in both patients and healthy volunteers because of its high protein binding affinity (85 to 97%) . The elimination half-life (t1/2) is about 8.1 to 20.5 hr in healthy volunteers and patients after administration of 40 to 120 mg orally. Moreover, its plasma clearance is 0.78 L/h (13 ml/min). It is extensively metabolized to 7 metabolites and excreted in urine therefore renal insufficiency has no influence in pharmacokinetic of gliclazide [5].The most notable effects are hypoglycaemia; gastrointestinal disturbances such as indigestion, epigastric pain and chest pain; dermatological reactions such as rash and transient itching; and biochemical abnormalities such as elevated serum creatinine, alkaline phosphatase, AST,and raised serum bilirubin. Cerebral vasodilation, mild disulfiram-like reactions and lassitude have been reported [6]. Gymnema sylvestre is used in different systems of medicine as a remedy for the treatment of diabetes, rheumatism, and cough. [7]. The major phytoconstituents of Gymnema sylvestre are gymnemic acids, gudmarin and saponins. Gymnemic acid (C43H68O14) is a pentacyclic triterpenoid and is the main active phytoconstituents of Gymnema sylvestre, exhibiting potent anti-diabetic activity [8]. Gymnemic acid show different physiological activities as lower blood glucose and levels of insulin in the diabetic subjects and inhibit intestinal glucose absorption [9].Recent times have witnessed increased incidence of diabetes across the globe, along with increased popularity of herbal products in the international market [10].
Rural people are still dependent on indigenous knowledge for health care that are being influenced by culture and socioeconomic aspects, providing a cheaper and accessible alternative to the high cost pharmaceutical remedies. In spite of the overwhelming influence and our dependence on modern medicine and tremendous advances in synthetic drugs, many people still rely on herbs the reason is that, if the herbs are used properly they don’t have any side effects. Hence, the study need to be subjected to pharmacological studies in order to discover their effect on the patients who are taking the treatment with synthetic drugs.
Materials and Methods
Drugs And Chemicals
Albino rats of either sex weighing between 180 and 250 g obtained from National institute of Nutrition India. These animals were maintained proper conditions in animal house of Vaageswari College of pharmacy {IAEC number VCP/2012/10/6/16}. streptozotocin (Neocare Naturals Pvt. Ltd, Hyderabad, India).Gymnema sylvestre collected from Mahadevepur forests India and Plant is authenticated by Dr.E.Narasimha Murthy, Department of Botany, Satavahana University, Karimnagar, Andhra Pradesh. {Specimen Accession Number ENM-100127}.
Extraction Procedure Of Gymnema Sylvestre
500gm of leaves of Gymnema sylvestre were taken, a small amount of dust present as dust was removed by shifting through a sieve of mesh number 30.initial identification was done by chewing few leaves for a minute. the mouth rinsed clean with water few grains of sugar were placed in mouth and disappearance of sugars sweetness was felt.1gm powdered material was shaken vigorously with water and examined for more than 30 minutes for froth test confirmed presence of saponin glycosides that is gymnemicacid.500gm of powdered dry leaf powder was packed soxhlet thimble and extracted continuously with 80% of ethanol until the material was completely exhausted. The final product was dark green amorphous powder after evaporation of solvent [11] .
Pretreatment
Albino rats of both gender weight between 180 and 250 g obtained from National institute of Nutrition, Hyderabad, India. These animals were maintained under standard conditions in animal house of Vaageswari College of pharmacy [IAEC number VCP/2012/10/6/16]. Each were kept in elevated wire cages and were provided with high fat food (carbohydrates: proteins: fat in 42:18:40 ratios) and water ad libitum for a period of 14 days [12].
Induction Of Diabetes In Rats By Using 60mg/Kg Of Streptozocin [13]
After 2 weeks of feeding with high fat food the rats were fasted for a period of 18 hours before induction of diabetes, and were injected intra-peritonially with a single dose of Streptozocin 60 mg/kg (Sigma–Aldrich, St. Louis, MO, USA), freshly dissolved in normal saline solution. After the administration, the rats had free access to food (normal pellet diet) and water ad libitum. Diabetes in rats was identified by moderate polydipsia and marked polyuria. After 3 days i.e. 72hrs of injection, the fasting blood glucose levels were determined by following glucose oxidase/peroxidase GOD/POD method using a commercial glucose estimation kit with UV-Visible Spectrophotometer at 505nm. The rats showing fasting blood glucose more than 150 mg/dL were considered diabetic rats and selected for the grouping in experimentation.
Study Design
The hyperglycemic rats are divided in to 6 groups 6 animals in each
Group I: Diabetic Control group (0.5% Na.CMC suspension)
Group II: Gymnema sylvestre (100 mg/kg)
Group III: Gymnema sylvestre (500 mg/kg)
Group IV: Gliclazide (40 mg/kg)
GroupV: Combination of Gliclazide (20mg/kg) + Gymnema sylvestre (500 mg/kg).
Group VI: Combination of Gliclazide (40 mg/kg) + Gymnema sylvestre (500 mg/kg). [14]
Pharmacokinetic Study in Diabetic Rats
Single Dose Study (Acute Study)
The diabetic rats were divided into 6 different treatment groups same as mentioned in study design and Daily treatment was carried for 21 days(3 weeks).Blood samples were collected from different groups on 0,7,14,21st day immediately after treatment. Blood samples were collected in to micro-centrifugal tubes containing sodium citrate from retro-orbital sinus under, mild ether anaesthesia. The blood samples were subjected to centrifugation at 3000 rpm for 10 min and plasma was stored at -200 C for analysis and determination of pharmacokinetic parameters as absorption rate constant, elimination rate constant, t1/2, V/F, CL/F, Tmax, Cmax, AUC 0-t, AUC 0 – ∞ .
Multiple Dose Study (Chronic Study)
The diabetic rats were divided into 6 different treatment groups same as mentioned in study design and Daily treatment was carried for 21 days(3 weeks).Blood samples were collected from different groups on 0,7,14,21st day immediately after treatment. Blood samples were collected in to micro-centrifugal tubes containing sodium citrate from retro-orbital sinus under, mild ether anaesthesia. The blood samples were subjected to centrifugation at 3000 rpm for 10 min and plasma was stored at -200 C for analysis and determination of pharmacokinetic parameters as absorption rate constant, elimination rate constant, t1/2, V/F, CL/F, Tmax, Cmax, AUC 0-t, AUC 0 – ∞ .
Pharmacodynamic Study in Diabetic Rats
Single Dose Study (Acute Study)
Adults albino rats weighing 180-250g with fasting serum glucose >150 mg/dl are considered as diabetic. The treatment was given as mentioned in study design. Different biochemical parameters as serum glucose, cholesterol, urea concentrations are measured at different time intervals of 0, 1, 2, 4, 8, 12 and 24hr by using semi auto analyzer. These values are considered as acute study values.
Multiple Dose Study (Chronic Study)
The diabetic rats were divided into 6 different treatment groups same as mentioned in study design and Daily treatment was carried for 21 days (3 weeks).Different biochemical parameters as glucose, cholesterol, urea concentrations of the overnight fasted rats were determined on 0,7,14,21st day using semi auto analyzer.[15]
Statistical Analysis
All data are expressed as Mean+Sd. For comparison amongst different groups, One-way analysis of variance (ANOVA) followed by Dunnet test was performed. P value fewer than 5% (P <0.05) was considered to be statistically significant.Pharmacokinetic data was calculated by using pk solver software and statistical analysis was done by INSTANT graph pad software.
Histopathological Studies
After the last blood glucose estimation, the rats were sacrificed and pancreas were excised and subjected to histopathological studies to determine the inflammatory and necrotic changes. The tissues were stained using H&E stain and observed under 100 × magnifications. [16].
Results & Discussion
Blood glucose levels mg/dl (0th,1st ,2nd,4th,8th, 12th and 24th Hour) after oral administration of Gymnema sylvestre, Gliclazide and combination of Gliclazide and Gymnema sylvestre in diabetic rats (n=6).
TREATMENT/Hours
BLOOD GLUCOSE LEVELS (mg/dL)
DIABETIC CONTROL
G S (DOSE)
GLICLAZIDE(DOSE)
GLICLAZIDE + G S (DOSE)
vehicle
100mg/kg
500mg/kg
40mg/kg
20mg/kg +500mg/kg
40mg/kg +500mg/kg
0th Hour BLOOD GLUCOSE LEVELS
402.2±11.6
411.2±10.4*
390.8±6.5*
386.11±8.13*
381.08±6.15*
378.24±6.73*
1st Hour BLOOD GLUCOSE LEVELS
463.6±9.8
409.6±1.20*
387.19±9.3*
380.09±9.05*
371.81±4.28*
356.93±5.66*
2nd HourBLOOD GLUCOSE LEVELS
464.1±9.3
349.2±12.9*
379.11±8.6*
375.13±4.51*
365.15±6.19*
344.08±9.03*
4th HourBLOOD GLUCOSE LEVELS
429.6±7.9
337.4±13.4*
365.26±4.8*
346.88±9.08*
340.86±5.68*
331.99±6.16*
8th HourBLOOD GLUCOSE LEVELS
440.1±8.4
298.2±4.5*
274.91±8.7*
261.81±1.35*
249.81±11.2*
240.18±8.28*
12th HourBLOOD GLUCOSE LEVELS
414.7±9.2
314.6±8.5*
294.7±5.5*
258.36±8.11*
245.81±8.24*
236.91±9.16*
24th HourBLOOD GLUCOSE LEVELS
415.8±11.2
323.4±9.6*
301.6±3.4*
264.18±10.16*
251.05±10.61*
241.18±8.11*
Values are given as mean± Standard deviation. *Statistical significance p < 0.05 (compared with the control group) G S -Gymnema sylvetsre n – number of animals used.
Blood cholesterol levels mg/dl (0th,1st ,2nd,4th,8th, 12th and 24th Hour) after oral administration of Gymnema sylvestre, Gliclazide and combination of Gliclazide and Gymnema sylvestre in diabetic rats (n=6).
BLOOD CHOLESTEROL LEVELS (mg/dL)
TREATMENT/Hours
DIABETIC CONTROL
G S (DOSE)
GLICLAZIDE(DOSE)
GLICLAZIDE + G S (DOSE)
vehicle
100mg/kg
500mg/kg
40mg/kg
20mg/kg +500mg/kg
40mg/kg +500mg/kg
0th HourBLOOD CHOLESTEROL LEVELS
199.3±12.5
208.2±9.4*
203.5±12.1*
200.81±10.35*
195.94±10.62*
190.16±4.92*
1st HourBLOOD CHOLESTEROL LEVELS
194.2±10.4
200.2±8.4*
195.5±14.2*
183.11±8.04*
179.18±9.16*
176.11±6.45*
2nd HourBLOOD CHOLESTEROL LEVELS
201.1±6.8
184.6±4.4*
181.6±7.4*
175.05±7.11*
169.15±8.16*
165.99±5.72*
4th HourBLOOD CHOLESTEROL LEVELS
204.9±12.5
175.2±7.8*
170.2±7.5*
154.24±9.16*
151.18±8.11*
149.03±6.91*
8th HourBLOOD CHOLESTEROL LEVELS
203.8±8.6
148.1±5.5*
145.9±8.4*
140.66±10.15*
136.15±5.18*
129.66±8.19*
12th HourBLOOD CHOLESTEROL LEVELS
210.6±9.5
154.9±6.3*
150.4±6.5*
138.48±11.81*
131.61±8.15*
126.48±11.94*
24th HourBLOOD CHOLESTEROL LEVELS
211.5±7.9
178.7±8.2*
169.6±2.4*
144.88±2.08*
134.84±9.06*
130.11±6.08*
Values are given as mean± Standard deviation. *Statistical significance p < 0.05 (compared with the control group) n – number of animals used G S – Gymnema sylvetsre
Blood urea levels mg/dl (0th,1st ,2nd,4th,8th, 12th and 24th Hour) after oral administration of Gymnema sylvestre, Gliclazide and combination of Gliclazide and Gymnema sylvestre in diabetic rats (n=6)
BLOOD UREA LEVELS (mg/dL)
TREATMENT/Hours
DIABETIC CONTROL
G S (DOSE)
GLICLAZIDE(DOSE)
GLICLAZIDE + G S (DOSE)
vehicle
100mg/kg
500mg/kg
40mg/kg
20mg/kg +500mg/kg
40mg/kg +500mg/kg
0th HourBLOOD.UREA LEVELS
63.72±7.5
64.8±5.5*
74.36±4.1*
71.52±5.9*
65.88±6.6*
63.78±4.2*
1st HourBLOOD UREALEVELS
63.18±2.6
64.72±7.8*
67.5±5.1*
70.38±5.5*
61.02±6.5*
60.48±2.6*
2nd HourBLOOD UREALEVELS
66.34±9.2
62.02±5.2*
65.24±7.1*
65.18±6.2*
58.78±6.32*
57.7±8.1*
4th HourBLOOD UREALEVELS
66.96±5.6
59.4±6.2*
57.24±5.4*
54.66±5.2*
56.16±6.35*
55.08±5.5*
8th HourBLOOD.UREALEVELS
68.04±4.5
50.76±6.4*
48.6±5.8*
51.23±71*
45.36±5.4*
43.2±4.4*
12th HourBLOOD UREALEVELS
69.12±4.4
54±6.6*
52.38±7.4*
53.26±5.2*
47.52±5.4*
45.36±7.4*
24th HourBLOOD UREALEVELS
68.24±9.0
61.56±5.2*
59.4±7.5*
56.36±5.1*
55.23±5.4*
52.35±4.4*
Values are given as mean± Standard deviation. *Statistical significance p < 0.05 (compared with the control group) G S – Gymnema sylvetsre n – number of animals used.
Blood glucose levels mg/dL (0th,7th, 14th and 21st day) after oral administration of Gymnema sylvestre, Gliclazide and combination of Gliclazide and Gymnema sylvestre in diabetic rats (n=6)
BLOOD GLUCOSE LEVELS (mg/dL)
TREATMENT/DAYS
DIABETIC CONTROL
G S (DOSE)
GLICLAZIDE(DOSE)
GLICLAZIDE+ G S (DOSE)
vehicle
100mg/kg
500mg/kg
40mg/kg
20mg/kg +500mg/kg
40mg/kg +500mg/kg
0ty dayBLOOD GLUCOSE LEVELS
410.2±4.5
419.2±2.2*
395.4±1.2*
390.4±3.1*
386.9±2.3*
370.8±1.3*
7th dayBLOOD GLUCOSE LEVELS
394.2±.2.4
238.1±2.4*
231.±3.1*
217.6±5.2*
211.5±1.34*
202.5±3.3*
14th dayBLOOD GLUCOSE LEVELS
385.8±3.4
180.5±1.5*
150.6±3.4*
120.5±2.6*
111.5±2.4*
106.8±2.4*
21st dayBLOOD GLUCOSE LEVELS
391.7±3.4
130.6±2.4*
121.5±2.5*
101.6±1.6*
98.8±1.4*
91.4±.3.4*
Values are given as mean± Standard deviation. *Statistical significance p < 0.05 (compared with the control group) G S – Gymnema sylvetsre n – number of animals used.
Blood cholesterol levels mg/dl (0th,7th, 14th and 21st day) after oral administration of Gymnema sylvestre, Gliclazide and combination of Gliclazide and Gymnema sylvestre in diabetic rats (n=6).
BLOOD CHOLESTEROL LEVELS (mg/dL)
TREATMENT/DAYS
DIABETIC CONTROL
G S (DOSE)
GLICLAZIDE(DOSE)
GLICLAZIDE+ G S (DOSE)
vehicle
100mg/kg
500mg/kg
40mg/kg
20mg/kg +500mg/kg
40mg/kg +500mg/kg
0ty dayBLOOD CHOLESTEROL LEVELS
193.7±11.5
188.3±9.5*
182.5±12.2*
186.5±6.3*
181.8±8.4*
175.6±9.2*
7th dayBLOOD CHOLESTEROL LEVELS
194.8±10.6
105.4±9.6*
102.4±8.4*
103.2±8.1*
94.6±6.6*
90.5±8.6*
14th dayBLOOD CHOLESTEROL LEVELS
186.2±9.5
86.5±9.23*
84.4±7.8*
77.5±8.24*
72.28±5.8*
69.6±10.8*
21st dayBLOOD CHOLESTEROL LEVELS
191.2±7.8
73.6±10.4*
70.±9.2*
69.2±8.4*
55.1±7.8*
51.2±6.4*
Values are given as mean± Standard deviation. *Statistical significance p < 0.05 (compared with the control group) G S – Gymnema sylvetsre n – number of animals used.
Blood urea levels mg/dl (0th,7th, 14th and 21st day) after oral administration of Gymnema sylvestre, Gliclazide and combination of Gliclazide and Gymnema sylvestre in diabetic rats (n=6).
BLOOD UREA LEVELS (mg/dL)
TREATMENT/DAYS
DIABETIC CONTROL
G S (DOSE)
GLICLAZIDE(DOSE)
GLICLAZIDE+ G S (DOSE)
vehicle
100mg/kg
500mg/kg
40mg/kg
20mg/kg +500mg/kg
40mg/kg +500mg/kg
0th dayBLOOD.UREA LEVELS
71.2±4.83
68.13±8.24*
69.6±6.51*
78.32±4.32*
74.25±4.33*
70.45±3.91*
7th dayBLOOD.UREA LEVELS
77.64±9.21
42.25±2.42*
38.12±4.01*
36.24±4.31*
33.21±4.21*
30.23±6.81*
14th dayBLOOD.UREA LEVELS
79.25±7.33
32±8.51*
32.05±6.03*
27.32±5.44*
25.14±9.14*
22.43±8.24*
21st dayBLOOD.UREA LEVELS
70.08±6.25
32.47±9.23*
30.12±8.54*
26.35±10.08*
23.75±9.94*
20.19±8.64*
Values are given as mean± Standard deviation. *Statistical significance p < 0.05 (compared with the control group) G S – Gymnema sylvetsre n – number of animals used.
Effect of Gymnema sylvestre on Pharmacokinetic parameters of Single dose administration of Gliclazide in diabetic rats(n=6)
Pharmacokinetic parameter
Units for Pharmacokinetic parameters
40mg/kg of GLICLAZIDE
GLICLAZIDE + Gymnema sylvestre (DOSE)
20mg/kg+500mg/kg
40mg/kg+500mg/kg
ka
h-1
0.91±0.04
0.52±0.11*
0.54±0.31*
ke
h-1
0.21±0.01
0.24±0.05*
0.25±0.08*
t1/2
h
9.19±0.11
9.14±0.83*
9.62±0.14*
V/F
(mg/kg)/(μg/ml)
22.25±0.82
28.32±3.14*
34.93±16.26*
CL/F
(mg/kg)/(μg/ml)/h
4.59±0.25
6.41±0.31*
8.64±0.61*
Tmax
h
2.04±0.08
2.48±0.19*
2.63±0.46*
Cmax
μg/ml
1.44±0.02
0.86±0.08*
0.98±0.08*
AUC 0-t
μg/ml*h
9.61±0.29
6.88±0.38*
8.98±0.11*
AUC 0 – ∞
μg/ml*h
10.64±0.48
7.45±0.36*
9.68±0.35*
Values are given as mean± Standard deviation. *Statistical significance p < 0.05 (compared with the control group) G S – Gymnema sylvetsre n – number of animals use
Effect of Gymnema sylvestre on Pharmacokinetic parameters of Multiple dose administration of Gliclazide in diabetic rats (n=6)
Pharmacokinetic parameter
Units for Pharmacokinetic parameters
40mg/kg of GLICLAZIDE
GLICLAZIDE + Gymnema sylvestre (DOSE)
20mg/kg+500mg/kg
40mg/kg+500mg/kg
ka
h-1
4.31±0.11
3.51±0.44*
3.92±0.25*
ke
h-1
0.46±0.08
0.55±0.09*
0.64±0.03*
t1/2
h
10.4±0.31
9.33±0.61*
9.41±0.88*
V/F
(mg/kg)/(μg/ml)
48.18±0.55
35.66±7.81*
55.06±11.43*
CL/F
(mg/kg)/(μg/ml)/h
9.02±0.36
8.51±0.99*
10.75±0.83*
Tmax
h
3.91±0.06
2.91±0.74*
4.81±0.59*
Cmax
μg/ml
3.68±0.09
0.86±0.08*
0.98±0.08*
AUC 0-t
μg/ml*h
19.83±0.41
11.52±0.26*
14.63±0.33*
AUC 0 – ∞
μg/ml*h
26.99±0.56
19.81±0.11*
21.53±0.51*
Values are given as mean± Standard deviation. *Statistical significance p < 0.05 (compared with the control group) G S – Gymnema sylvetsre n – number of animals used.
Volume of islet cells in pancreas in different groups after multiple dose administration of gliclazide. (n=6).
GROUP
Volume of islets (mm3/mm3) / Volume of pancreas (mm3/mm3)
Diabetic Control
0.082 ± 0.004
G S (100 mg/kg, p.o.)
0.195 ± 0.052*
G S (500 mg/kg, p.o.)
0.244 ± 0.007*
Gliclazide (40 mg/kg, p.o.)
0.137 ± 0.009
Gliclazide (20 mg/kg, p.o.) +G S (500 mg/kg, p.o.)
0.241 ± 0.036*
Gliclazide (40 mg/kg, p.o.) +G S (500 mg/kg, p.o.)
0.285 ± 0.043*
Volume of islet cells in pancreas in different groups after multiple dose administration of gliclazide. (n=6).
The histopathological studies reveal that the combination of gliclazide (40 mg/kg) and Gymnema sylvestre not only increased the volume of islets and also recovered partially destroyed beta cells.
Pharmacodynamic Study
The combination of high dose of gliclazide (40 mg/kg) with 500mg/kg Gymnema sylvestre showed maximum hypoglycaemic action, decrease in serum cholesterol, urea levels. The influence produced by combination of gliclazide (20 mg/kg) with Gymnema sylvestre was greater than the hypoglycaemic action produced by Gymnema sylvestre (500 mg/kg) alone, but less than gliclazide (40 mg/kg).
Pharmacokinetic Study
The pharmacokinetic study shows that, 27% decreased in AUC( 0 – ∞) in 500mg/kg of Gymnema sylvestre and 20mg/kg of gliclazide. 47% decrease AUC( 0 – ∞) in 500mg/kg of Gymnema sylvestre and 40mg/kg of gliclazide. C max was decreased by 34% in 500mg/kg of Gymnema sylvestre and 20mg/kg of gliclazide., 53% in 500mg/kg of Gymnema sylvestre and 40mg/kg of gliclazide that was attributed by significant decrease in absorption rate constant Ka by about 37% in Lower dose of 500mg/kg of Gymnema sylvestre and 20mg/kg of gliclazide, 41% in 500mg/kg of Gymnema sylvestre and 40mg/kg of gliclazide. Significantly increase in clearance 38 % in 500mg/kg of Gymnema sylvestre and 20mg/kg of gliclazide. 88% in 500mg/kg of Gymnema sylvestre and 40mg/kg of gliclazide compared to 40mg/kg Gliclazide group.
Conclusion
The interaction of modern medicine with herbs is a developing area with research activities being carried out in different parts of the world. The interaction of herbs with various classes of drugs have been reported and some drugs such as terfenadine and astemizole from the market due to such interactions.
The interaction appears to be pharmacokinetic interaction at absorption, elimination. Gymnema sylvestre inhibits the absorption of oral hypoglycemics that results in a significant decrease in the bioavailability of the later and combination group with a lower dose of oral hypoglycemics produced increment to the volume of islets in pancreas compare to individual treatment. Since the interaction was seen in rats it is likely to occur in humans leading to decreased activity of oral hypoglycemic that can need dose adjustments. Hence care must be taken when the combination is prescribed for clinical benefit in diabetic patients. The present study warrants next plan to find out the relevance of the interaction in human beings.
Acknowledgement
I take this privilege and pleasure to acknowledge the contributions of many individuals who have been inspirational and supportive throughout my work undertaken and endowed with the precious knowledge to see success in my endeavour.
References
- Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes.Diabetes Care 1989; 12:553-64.
- Izzo A A. Herb-drug interactions: an overview of the clinical evidence, Fundamental & Clinical Pharmacology, 19, 2005, 1-16.
- Baba S. Double-blind randomized control study with gliclazide Clin Eva 1983; 11(1):51-94.
- Hoich RI, Ng FM: lnsulin-potentiating action of gliclazide (Diamicron) Pharmacol Res Commun 1986; 18(5):419-430
- Holmes B et coll: Gliclazide. A preliminary review of its pharmacodynamic properties therapeutic efficacy in diabetes mellitus Drugs 1984; 27:301-327.
- Kuwashima J et coll: Inhibition by gliclazide of platelet adhesiveness andaggregation in the rabbit made diabetic by alloxan Yakugaku Zasshi 1979; 99(1):50-64.
- Patel K, Gadewar M, Tripathi R, Patel DK (2012).Pharmacological and analytical aspects of gymnemic acid: a concise report. Asian Pac J Trop Dis. 2(5): 414-416.
- Shivani Vaidya (2011). Review on gymnema: an herbal medicine for diabetes management. Pharmacia. 1(2): 1-6.
- Ankit Saneja, Chetan Sharma, Aneja KR, Rakesh Pahwa(2010).GymnemaSylvestre Gurmar): A Review, Der Pharmacia Lettre, 2(1): 275-284.
- John B Classen (2012). Review of Evidence that Epidemics of Type 1 Diabetes and Type 2 Diabetes/ Metabolic Syndrome are Polar Opposite Responses to Iatrogenic Inflammation. Current Diabetes Reviews.8(6): 413-418.
- Farzana C., Muhammad H.R. Isolation and characterization of gymnemic acid from Indigenous Gymnema sylvestre. 2010;J APP Pharm,3(2):60-65.
- Reed, M.J., Meszaros, K., Entes, L.J., Claypool, M.K., Pinkett, J.G., Gadbois, T.M., Reaven G.M. (2000) A new rat model of type 2 diabetes: The fat-fed, streptozotocin- treated rat. Metabolism clinical and experimental, Vol 49, Issue 11, Pages 1390-1394.
- Thulesen, J., Orskov, C., Holst, J.J., Poulsen, S.S., (1997) Short term insulin treatment prevents the diabetogenic action of streptozotocin in rats. Endocrinology Vol. 138, No. 1 62-68.
- Talari, R.,Varshosaz, J., Mostafavi, S.A., Nokhodchi, A. (June 2010) Gliclazide Microcrystals Prepared by Two Methods of In Situ Micronization: Pharmacokinetic Studies in Diabetic and Normal Rats. AAPS PharmSciTech, Vol. 11, No. 2.
- Shavi, G.V., Usha, Y.N., Armugam, K., Ranjan, O.P., Ginjupalli, K., Pandey, S., Udupa, N. (2010) Enhanced dissolution and bioavailability of gliclazide using solid dispersion techniques. International Journal of Drug Delivery 2, 49-57.
- Navetabhishekam, S.N., Asad, M., Prasad, V.S. (2009) Pharmacodynamic interaction of Momordica charantia with rosiglitazone in rats, Chem Biol Interact. 177,247– 253.
Leave a Comment